An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics to Participate in Two Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in two investor conferences: the Stifel 2022 Healthcare Conference on November 15, 2022, hosting 1x1 investor meetings, and the Jefferies London Healthcare Conference on November 17, 2022, featuring a fireside chat at 10:50 a.m. EST. An archived recording of the fireside chat will be available for 90 days on their website. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, leveraging its unique approach to advance drug candidates.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that management will participate in two upcoming investor conferences.
The Stifel 2022 Healthcare Conference on November 15, 2022 – management will attend and host 1x1 investor meetings.
The Jefferies London Healthcare Conference on November 17, 2022 at 10:50 a.m. EST – management will participate in an in-person fireside chat.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on understanding the role that carbohydrates play on the surface of every living cell and applying specialized chemistry to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in diverse disease states, including cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is in Rockville, MD in the BioHealth Capital Region. Learn more atwww.glycomimetics.com.
What are the upcoming investor conferences for GlycoMimetics (GLYC)?
GlycoMimetics will attend the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022.
When is GlycoMimetics participating in the Jefferies London Healthcare Conference?
GlycoMimetics will participate in the Jefferies London Healthcare Conference on November 17, 2022, at 10:50 a.m. EST.
Where can I find the archived recording of GlycoMimetics' fireside chat?
The archived recording of GlycoMimetics' fireside chat will be available for 90 days on their website.
What is the focus of GlycoMimetics' drug development?
GlycoMimetics focuses on developing glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases.
